Pattern analysis of antidepressant response to fluoxetine.

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Major depressive disorder (MDD) is a prevalent and debilitating mental health condition.
• Effective pharmacological treatments are crucial for managing MDD symptoms.
• Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for depression.

Purpose of the Study:

• To evaluate the efficacy of fluoxetine compared to placebo in treating unipolar major depressive disorder.
• To assess the correlation between symptom changes and global improvement ratings.

Main Methods:

• A 6-week, double-blind, placebo-controlled trial involving seventy patients with unipolar MDD.
• Patients were assessed using the Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale.
• Endpoint analyses compared treatment groups and correlated HAM-D score changes with CGI improvement ratings.

Main Results:

• High correlations were observed between changes in HAM-D scores and CGI improvement ratings.
• Significant differences favoring fluoxetine were found in patients with moderate depression (baseline HAM-D score ≥ 20).
• A persistent pattern of improvement was noted in 27% of fluoxetine recipients versus 0% of placebo recipients.

Conclusions:

• Fluoxetine shows significant efficacy in treating moderate major depressive disorder.
• Physician and patient global assessments are reliable indicators of treatment response.
• The study supports the use of fluoxetine for major depressive disorder, particularly in patients with moderate symptom severity.